Alpha Tau Medical Ltd Stock Price, News & Analysis

Alpha Tau Medical (NASDAQ: DRTS) announced positive interim data from multiple clinical trials of its Alpha DaRT® cancer therapy. Key highlights include:

In pancreatic cancer trials across Canada and Israel (41 patients), the treatment showed a 100% delivery success rate, 18% objective response rate, and 91% disease control rate. Ad-hoc analyses suggested improved median overall survival compared to historical studies.

In head and neck cancer trials combining Alpha DaRT with pembrolizumab (8 patients), results showed a 75% systemic objective response rate and 37.5% systemic complete response rate, significantly higher than historical benchmarks.

The company received FDA approval for a U.S. pilot study combining Alpha DaRT with first-line chemotherapy in metastatic pancreatic cancer patients, and French approval for a multicenter trial with capecitabine in locally advanced pancreatic cancer.

Additional case studies demonstrated promising results in treating liver metastases, lung cancer, and rectal cancer patients.

Alpha Tau Medical (NASDAQ: DRTS), developer of the Alpha DaRT® cancer therapy, announced two significant upcoming events. First, an abstract on pancreatic adenocarcinoma trials will be presented at the 2025 ASCO Gastrointestinal Cancers Symposium (January 23-25, 2025) in San Francisco. The presentation will occur during Poster Session B on January 24.

Additionally, the company will host an R&D Update Day on January 27, 2025, where they will discuss new data from both Israeli and Canadian pancreatic cancer trials, including feasibility, safety, tumor response, and survival metrics. The update will also cover findings from trials combining Alpha DaRT with pembrolizumab for head and neck cancer treatment.

Alpha Tau Medical (Nasdaq: DRTS) announced changes to its Board of Directors, with Maya Netser joining and Meir Jakobsohn stepping down but continuing as an advisor. Netser brings over 25 years of experience as a C-level technology leader, board member, and investor. She is the founder of Quantum Leap VC and previously served as CEO of Cabaret Biotech, where she led the company to a successful acquisition by Kite Pharma and Gilead Sciences.

Netser's appointment comes at a strategic time as Alpha Tau expands into internal organ treatments with its Alpha DaRT® cancer therapy. She holds an LL.B and MBA from Tel Aviv University and is a member of the Israeli National Team of Directors.

Alpha Tau Medical (NASDAQ: DRTS), developer of the Alpha DaRT® alpha-radiation cancer therapy, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. CEO Uzi Sofer and CFO Raphi Levy will deliver a corporate overview and update on January 16, 2025, from 9:45 AM to 10:25 AM PT at the Westin St. Francis in San Francisco. The presentation will highlight recent company achievements and upcoming data milestones. Institutional investors can schedule one-on-one meetings with the executives through their J.P. Morgan representatives. A webcast of the presentation will be available on the company's website in the Investor Relations section.

Alpha Tau Medical (NASDAQ: DRTS), developer of the Alpha DaRT® alpha-radiation cancer therapy, has announced its participation in the upcoming Ladenburg Oncology Innovators & Investors Symposium.

CFO Raphi Levy will represent the company at this virtual event, scheduled for December 12, 2024, from 11:00 AM to 11:25 AM EST. The format will include both a presentation and one-on-one meetings, which can be arranged through Ladenburg representatives.

Alpha Tau Medical (NASDAQ: DRTS) reported Q3 2024 financial results and corporate updates. Key developments include acceptance into FDA's Total Product Life Cycle Advisory Program (TAP) for Alpha DaRT® treatment of recurrent glioblastoma, first patient treatment in a recurrent lung cancer study in Israel, and FDA approval for a multi-center study treating recurrent cutaneous squamous cell carcinoma. The company reported a net loss of $22.3 million ($0.32 per share) for the nine months ended September 30, 2024. Cash position stands at $68.4 million, providing runway for at least two years.

Alpha Tau Medical (NASDAQ: DRTS), developer of the Alpha DaRT® alpha-radiation cancer therapy, announces CFO Raphi Levy's participation in two major healthcare conferences. Levy will attend the Citi 2024 Global Healthcare Conference on December 3rd in Miami, FL, participating in one-on-one meetings from 8:30 AM to 4:30 PM EST. Additionally, he will join the Piper Sandler 36th Annual Healthcare Conference on December 5th in New York, NY, featuring a fireside chat from 10:00-10:25 AM EST along with one-on-one meetings.

Alpha Tau Medical (NASDAQ: DRTS, DRTSW) has been accepted into the FDA's Total Product Life Cycle (TPLC) Advisory Program (TAP) Pilot to accelerate market access for Alpha DaRT® in treating recurrent glioblastoma multiforme (GBM). This follows the company's previous Breakthrough Device Designation for this indication. TAP aims to expedite patient access to innovative medical devices by providing early, frequent, and strategic communications with the FDA and facilitating engagement with key stakeholders.

The program offers tailored assistance from FDA TAP advisors to advance devices to market, focusing on product lifecycle regulation, payer coverage policies, and integration of patient insights. With an estimated 14,000 new GBM diagnoses per year in the U.S. and low five-year survival rates, Alpha Tau sees this as a important step in their strategy to treat internal organs with high unmet medical needs.

Alpha Tau Medical (NASDAQ: DRTS, DRTSW) has treated its first patient with recurrent lung cancer using the Alpha DaRT® therapy at Hadassah Medical Center in Jerusalem, Israel. The clinical trial aims to treat up to ten patients with recurrent tumors in the mediastinum area, allowing concurrent use of other therapies if indicated. The study will assess the safety and feasibility of delivering Alpha DaRT sources into the lung using an endobronchial ultrasound (EBUS) procedure, as well as evaluate the efficacy of Alpha DaRT for this indication.

Lung cancer is the leading cause of cancer-related deaths worldwide, with almost 2.5 million new cases detected annually. In the U.S., it's the third most common cancer, with an estimated 210,000 new cases per year. The Alpha DaRT treatment offers a potential new approach for patients with treatment options, especially those who have already undergone conventional radiation therapy.